Carmelo Rizzari

Monza, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 139 publications

Sinusoidal obstruction syndrome in children with B-acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin: Results from the ITCC-059 trial.

Sinusoidal obstruction syndrome in children with B-acute lymphoblastic leukemia (B-ALL) treated with inotuzumab ozogamicin: Results from the ITCC-059 trial.

Journal: HemaSphere
Published: May 06, 2026

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus.

Optimizing safety and efficacy of asparaginase and blinatumomab therapy in frontline acute lymphoblastic leukemia regimens in diverse health care settings-international expert consensus.

Journal: Cancer
Published: April 02, 2026

"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy.

"Per aspera ad astra": the transformative contribution of glucarpidase to the improved management of delayed methotrexate elimination after high-dose therapy.

Journal: Expert review of hematology
Published: March 10, 2026

When Neuromuscular Weakness Is Not Chemotherapy‑Related: Spinal Muscular Atrophy Type II Diagnosed After Acute Lymphoblastic Leukemia Onset in a 1-Year-Old Child: A Case Report and Review of the Literature.

When Neuromuscular Weakness Is Not Chemotherapy‑Related: Spinal Muscular Atrophy Type II Diagnosed After Acute Lymphoblastic Leukemia Onset in a 1-Year-Old Child: A Case Report and Review of the Literature.

Journal: Pediatric blood & cancer
Published: March 05, 2026

The very rare association between T-cell acute lymphoblastic leukemia and down syndrome: a case report and review of the literature.

The very rare association between T-cell acute lymphoblastic leukemia and down syndrome: a case report and review of the literature.

Journal: Frontiers in pediatrics
Published: February 28, 2026

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Correction: Pourroy et al. High-Dose Methotrexate at All Ages: Safety, Efficacy, and Outcomes from the HDMTX European Registry. Cancers 2026, 18, 124.

Journal: Cancers
Published: February 26, 2026

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Measurable Residual Disease-Dependent Unfavorable Outcomes in Pediatric PAX5-Rearranged B-Acute Lymphoblastic Leukemia.

Journal: Blood
Published: February 13, 2026

Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.

Improved outcomes of the refined risk-stratification and risk-adapted therapy in children with acute myeloid leukemia: final results of the AIEOP AML 2013.

Journal: Journal of hematology & oncology
Published: February 08, 2026

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation.

Journal: Clinical pharmacokinetics
Published: February 05, 2026

Successful Treatment of Multirefractory Immune Thrombocytopenia in Rubinstein-Taybi Syndrome With Combined Rituximab and Eltrombopag.

Successful Treatment of Multirefractory Immune Thrombocytopenia in Rubinstein-Taybi Syndrome With Combined Rituximab and Eltrombopag.

Journal: Pediatric blood & cancer
Published: January 08, 2026

clinTALL: machine learning-driven multimodal subtype classification and treatment outcome prediction in pediatric T-ALL.

clinTALL: machine learning-driven multimodal subtype classification and treatment outcome prediction in pediatric T-ALL.

Journal: Genome medicine
Published: December 22, 2025

Encouraging Outcomes in Pediatric Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Results From the Italian HLH Registry.

Encouraging Outcomes in Pediatric Malignancy-Associated Hemophagocytic Lymphohistiocytosis: Results From the Italian HLH Registry.

Journal: American journal of hematology
Published: December 11, 2025
Showing 1-12 of 139

Last Updated: 09/26/2026